News | Linear Accelerators | January 04, 2021

RAD Technology Medical Systems to Expand their Patented Modular Building Portfolio

RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

January 4, 2021 — RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

In spite of the global pandemic, RAD has continued to grow and design new radiotherapy facility solutions that will allow hospitals and cancer centers to keep pace with the rapid advancements in radiation therapy equipment and employ the latest treatment techniques to improve outcomes for their patients.

RAD's newest radiotherapy offering will provide end users with three different building configuration options. Customers will be able to pick the configuration they want based on their programming needs and space availability. In addition, they will be able to quickly and easily add space to the facility if and as the need for more arises.

The basic configuration provides a radiotherapy treatment bunker and control room specifically designed to accommodate a low energy self-shielded linac. The second configuration includes gowning space, a restroom and a multipurpose space that can be used as an office, exam room or an alternate entry/waiting area. The final configuration builds upon the first two and provides an additional restroom, nurses' station, waiting & reception and more flex space for exam, office and/or physics/dosimetry.  This phased modular approach allows for a variety of configurations ranging from a temporary adjunctive radiotherapy bunker to a complete and permanent standalone radiotherapy treatment facility.

As with all of RAD's facilities, whether permanent or temporary, this new design will be built using off site construction methods leading to less construction taking place on site, minimizing the disruption for doctors, patients and staff.  It also takes advantage of RAD's patented granular shielding system. This unique construction method and shielding system allow the bunker to be assembled on site in a matter of days and treating patients in less than a month. By catering to this new breed of low energy, self-shielded equipment which is gaining a foothold in the radiotherapy market, RAD can offer a flexible array of options and deploy a functional and attractive facility with a small footprint at a variety of sites.

"We are excited to expand our portfolio with this new radiotherapy facility that will provide the perfect accommodation for the newest generation of linacs on the market," said Kenneth Wright, RAD's Vice President of Sales and Business Development.  "We are looking forward to 2021, and to deploying this new style of bunker and cancer center in Europe and the U.S."

For more information: www.radtechnology.com

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.